biology-technology-1/professor-steven-ley-of-university-of-cambridge-will-present-free-webinar---26apos-3bapplication-of-the-reactir-flow-cell-to-continuous-processing-tec-14728-3/;msg90356

Breaking Biology Technology:Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2 Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3 Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4 Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5 Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2 Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3 Endologix Appoints Dan Lemaitre to its Board of Directors 2 YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 2 YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 3 YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 4

[0] Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia [0] Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development [0] Endologix Appoints Dan Lemaitre to its Board of Directors [0] YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT

Breaking Medicine Technology:Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2 ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2 ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3 ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4 Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2 Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3 Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4 Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5 Pausing Hormone Therapy Doesnt Cut Mammogram Recalls 47850 1 Pausing Hormone Therapy Doesnt Cut Mammogram Recalls 47850 2 U S Civil Rights Commission to Hold Public Briefing on Health Care Disparities Between Minorities and Non Minorities and Business Meeting 47848 1 U S Civil Rights Commission to Hold Public Briefing on Health Care Disparities Between Minorities and Non Minorities and Business Meeting 47848 2 U S Civil Rights Commission to Hold Public Briefing on Health Care Disparities Between Minorities and Non Minorities and Business Meeting 47848 3 Anthem Blue Cross in California Provides More Members With Access to Comprehensive Transparency Tool 47846 1 Anthem Blue Cross in California Provides More Members With Access to Comprehensive Transparency Tool 47846 2 Anthem Blue Cross in California Provides More Members With Access to Comprehensive Transparency Tool 47846 3

[0] Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer [0] ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)[0] Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy